Evidence map›Paper›PMID 23523818›Full record

ArticleInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases2013

Intra-host evolutionary rates in HIV-1C env and gag during primary infection.

Vlad Novitsky, Rui Wang, Raabya Rossenkhan, Sikhulile Moyo, M Essex

Abstract read
In one paragraph

Article in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  7. Genome-wide association study reveals genetic variants associated with HIV-1C infection in a Botswana study population.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Vlad NovitskyHarvard School of Public Health AIDS Initiative, Department of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Avenue, Boston 02115, MA, USA; Botswana-Harvard AIDS Institute, P/Bag BO 320, Gaborone, Botswana. Electronic address: vnovi@hsph.harvard.edu.
Rui Wang
Raabya Rossenkhan
Sikhulile Moyo
M Essex
Harvard University · USBotswana Harvard AIDS Institute Partnership · BWUniversity of Botswana · BW

Funding

INTERNATIONAL TRAINING IN AIDS-RELATED EPIDEMIOLOGYD43TW000004 · FIC · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 1988 to 2012
$13.4M
STATISTICAL METHODS IN AIDS RESEARCHR37AI024643 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUGHES, MICHAEL DAVID · 2001 to 2010
$2.8M
Markers of Viral Set Point in Primary HIV-1C InfectionR01AI057027 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI NOVITSKY, VLADIMIR A · 2005 to 2009
$2.2M
STATISTICAL METHODS IN AIDS RESEARCHR01AI024643 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI HUGHES, MICHAEL DAVID · 1987 to 2014
$1.7M
HCV Treatment Cost-Effectiveness in 3 IDU PopulationsK01DA017179 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHACKMAN, BRUCE R · 2004 to 2008
$840k
Mutational pathways in early HIV infection: novel guide to immunologic analysesR21AI087493 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI NOVITSKY, VLADIMIR A · 2010 to 2011
$439k
Early and acute HIV-1 subtype C infection in BotswanaR21AI055297 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI NOVITSKY, VLADIMIR A · 2003 to 2004
$378k
FIC NIH HHS D43 TW000004NIAID NIH HHS R01 AI024643NIAID NIH HHS R01 AI057027NIAID NIH HHS R21 AI055297NIAID NIH HHS R21 AI087493NIAID NIH HHS R37 AI024643NIAID NIH HHS R37 AI24643
6 · The paper itself

Abstract

backgroundHIV-1 nucleotide substitution rates are central for understanding the evolution of HIV-1. Their accurate estimation is critical for analysis of viral dynamics, identification of divergence time of HIV variants, inference of HIV transmission clusters, and modeling of viral evolution.

methodsIntra-patient nucleotide substitution rates in HIV-1C gag and env gp120 V1C5 were analyzed in a longitudinal cohort of 32 individuals infected with a single viral variant. Viral quasispecies were derived by single genome amplification/sequencing from serially sampled blood specimens collected at median (IQR) of 5 (4-6) times per subject from enrollment (during Fiebig stages II to V) over a median (IQR) of 417 (351-471) days post-seroconversion (p/s). HIV-1C evolutionary rates were estimated by BEAST v.1.7 using a relaxed lognormal molecular clock model. The effect of antiretroviral therapy (ART) on substitution rates in gag and env was assessed in a subset of six individuals who started ARV therapy during the follow-up period.

resultsDuring primary HIV-1C infection, the intra-patient substitution rates were estimated at a median (IQR) of 5.22E-03 (3.28E-03-7.55E-03) substitutions per site per year of infection within gag, and 1.58E-02 (9.99E-03-2.04E-02) substitutions per site per year within env gp120 V1C5. The substitution rates in env gp120 V1C5 were higher than in gag (p<0.001, Wilcoxon signed rank test). The median (IQR) relative rates of evolution at codon positions 1, 2, and 3 were 0.73 (0.48-0.84), 0.67 (0.52-0.86), and 1.54 (1.21-1.71) in gag, and 1.01 (0.86-1.15), 1.05 (0.99-1.21), and 0.86 (0.67-0.94) in env gp120 V1C5, respectively. A first to the third position codon rate ratio >1.0 within env was found in 25 (78.1%) cases, but only in 4 (12.5%) cases in gag, while a second to the third position codon rate ratio >1.0 in env was observed in 26 (81.3%) cases, but in gag only in 2 (6.3%) cases (p<0.001 for both comparisons, Fisher's exact test). No ART effect on substitution rates in gag and env was found, at least within the first 3-4 months after ART initiation. Individuals with early viral set point ⩾4.0 log10 copies/ml had higher substitution rates in env gp120 V1C5 (median (IQR) 1.88E-02 (1.54E-02-2.46E-02) vs. 1.04E (7.24E-03-1.55E-02) substitutions per site per year; p=0.017, Mann-Whitney sum rank test), while individuals with early viral set point ⩾3.0 log10 copies/ml had higher substitution rates in gag (median (IQR) 5.66E-03 (3.45E-03-7.94E-03) vs. 1.78E-03 (4.57E-04-5.15E-03); p=0.028; Mann-Whitney sum rank test).

conclusionsThe results suggest that in primary HIV-1C infection, (1) intra-host evolutionary rates in env gp120 V1C5 are about 3-fold higher than in gag; (2) selection pressure in env is more frequent than in gag; (3) initiation of ART does not change substitution rates in HIV-1C env or gag, at least within the first 3-4 months after starting ART; and (4) intra-host evolutionary rates in gag and env gp120 V1C5 are higher in individuals with elevated levels of early viral set point.

Indexed as

AdultAnti-Retroviral AgentsCodonCohort StudiesEvolution, MolecularFemalegag Gene Products, Human Immunodeficiency VirusHIV-1HIV Envelope Protein gp120HIV InfectionsHost-Pathogen InteractionsHumansMaleMiddle AgedMutationStatistics, NonparametricAnti-Retroviral AgentsCodongag Gene Products, Human Immunodeficiency VirusHIV Envelope Protein gp120Evolutionary ratesHIV-1Primary infectionSubstitution ratesSubtype C

Identifiers

PMID23523818
PMCPMC3759599
OpenAlexW2074395764

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.